Current Update on the Abiraterone Expanded Access Trial

The latest from Jan Manarite of PCRI about the getting early access to Abiraterone for men with advanced prostate cancer and who have failed chemotherapy: Abiraterone expanded Access Trial Site Contact Info – 2/7/11 (800) 457-6399 M-F, 9am –5pm, EST TRIAL link: http://www.clinicaltrials.gov/ct2/show/NCT01217697?term=abiraterone&recr=Open&rank=6 Basic Criteria: 1. testosterone less than 50 2. metastatic 3. no brain [...]

Malecare Offers Free Access to CenterWatch’s Data Base of Clinical Trials for Prostate & Testicular Cancer

Malecare is proud to announce that we are now partnering with the Clinical Trials Resource Center. This partnership allows us to offer you, through our web site (www.malecare.org), CenterWatch’s data base of clinical trials that are being conducted both in the United States and internationally. CenterWatch is the leading publisher of information on clinical research [...]

Malecare’s New Clinical Trial Info Site

Malecare http://malecare.org/ announces it’s new, comprehensive and up-to-date clinical trials database and information pages. Click on the “Clinical Trials Center” button on the left side of our home page. Information on: Listing of Current Clinical Trials Listing of Studies at the National Institutes of Health FDA Drug Approvals …Oncology Research Centers and New Medical Therapies [...]

A New Strategey – Fight Cancer with Cancer – On The Horizon

Thinking out of the box, a new concept to fight cancer, including prostate cancer, has been developed. The strategy is simple, fight cancer with cancer! In a very small phase one trial researchers at the Rogosin Institute have taken encapsulated tumor cells from mice and made a bead from a seaweed-derived sugar called agarose. Then, [...]

Abiraterone Acetate Now Available in the North East, United States

From Jan Manarite: To all, Many of you who have advanced prostate cancer may have been watching a drug in development called Abiraterone Acetate. It is not yet FDA approved, but trials look very good, and side effects appear to be very few. Most common side effects are fluid retention (30.5%), and low potassium (17.1%). [...]

Go to Top